Back to results
US 2015/0104507 A1Published application
Formulation of lacosamide
AssigneeUCB Pharma S.A.
InventorsWilli CAWELLO, Martin Alexander SCHUBERT
Life of this patent
Estimating the term…
Abstract
A modified release formulation of lacosamide.
Claims26
1-24. (canceled)
A method for the alleviation and/or treatment of a central nervous system disease comprising orally administering a solid controlled release formulation of lacosamide to a subject in need thereof, wherein the formulation comprises lacosamide in an amount of 20 to 95 wt % relative to the total amount of the formulation, and a release controlling agent, wherein
- (a) an amount of about 8.5 wt % to about 50 wt % of lacosamide relative to the total lacosamide content of the formulation is released within 1 h, and
- (b) an amount of about 15 wt % to about 72 wt % of lacosamide relative to the total lacosamide content of the formulation is released within 2 h, and
- (c) an amount of about 28 wt % to about 95 wt % of lacosamide relative to the total lacosamide content of the formulation is released within 4 h,
- when the in-vitro release of lacosamide is measured according to USP (edition 24) method <711>, dissolution apparatus 2, in 900 mL of 0.1N HCl at 75 rpm, and
- wherein the formulation is administered twice daily and after administration of the formulation at least one of the following occurs:
- (i) a peak-to-trough fluctuation (PTF) of between about 8.5% and about 32%;
- and
- (ii) time after each administration to reach the maximum lacosamide plasma concentration at steady state (Tmax,ss) is between about 3 hours and 6 hours.
5 more elements
Dependencies are inferred from the claim text.